DNASE1L3 and systemic lupus erythematosus: Outcomes included SLE Disease Activity Index (SLEDAI), Physician/Parent Global Assessment (GA), and daily glucocorticoid (GC) dose, and adverse events were collected.<h4>Results</h4>Seven patients with mutations in <i>C1q, DNase1L3, PRKCD</i>, and <i>NRAS</i> were included.